Technology
Health
Biotechnology

SenesTech

$1.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (1.80%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell SenesTech and other stocks, options, ETFs, and crypto commission-free!

About

SenesTech, Inc. engages in the development and commercialization of a proprietary technology for the management of animal pest populations, primarily rat populations through fertility control. Its first fertility control product candidate is ContraPest. Read More The company was founded by Loretta P. Mayer and Cheryl A. Dyer in July 2004 and is headquartered in Flagstaff, AZ.

Employees
44
Headquarters
Flagstaff, Arizona
Founded
2004
Market Cap
39.90M
Price-Earnings Ratio
Dividend Yield
Average Volume
997.24K
High Today
$1.80
Low Today
$1.65
Open Price
$1.80
Volume
167.34K
52 Week High
$2.37
52 Week Low
$0.355

Collections

Technology
Health
Biotechnology
2016 IPO
US
North America
Female CEOs

News

Seeking AlphaMay 16

SenesTech reports Q1 results and appoints new chief executive

SenesTech (SNES -7.9% ) says that Q1 results reflect temporary disruptions due to implementation of end user sales and marketing strategy, delay in deployments due to anticipated seasonal reduction in rodent activity during the quarter and the transition to the removal of ContraPest's 'restricted use only' status at the state level.

160
Seeking AlphaMay 16

SenesTech, Inc. CEO Ken Siegel on Q1 2019 Results - Earnings Call Transcript

SenesTech, Inc. (NASDAQ:SNES) Q1 2019 Earnings Conference Call May 15, 2019 5:00 PM ET Company Participants Robert Blum - Managing Partner, Lytham Partners, LLC Phoenix Loretta Mayer - Chief Scientific Officer and Chairman of the Board Kenneth Siegel - Chief Executive Officer Edward Albe - Senior Vice President of Commercialization Tom Chesterman - Chief Financial Officer Cheryl Dyer - Chief Research Officer Conference Call Participants Kevin Ellich - Craig-Hallum Capital Group LLC Operator Good ...

128
Markets InsiderMay 6

California Bill AB1788 to Ban SGAR Rodenticides Clears Assembly

FLAGSTAFF, Ariz., May 6, 2019 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announces that California's AB1788, which will ban the use of Second Generation Anticoagulant Rodenticides (SGARs), has been passed by the State Assembly. "With this, California has moved a step closer to the creation of the California Ecosystems Protection Act of 2019 which will prohibit the use of the four major Second Genera...

537

Earnings

-$0.31
-$0.24
-$0.17
-$0.10
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.10 per share
Actual
-$0.10 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.